top of page

SABINA

MEN1611 MONOTHERAPY OR IN COMBINATION WITH ERIBULIN FOR PIK3CA/PTEN ALTERED METAPLASTIC BREAST CANCER

CLINICAL TRIAL DETAILS

THE PRIMARY OBJECTIVE FOR COHORT A IS TO ASSESS THE EFFICACY OF THE COMBINATION OF MEN1611 WITH ERIBULIN AS DETERMINED BY CLINICAL BENEFIT RATE IN UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HR-KNOWN/HER2-NEGATIVE, PIK3CA/PTEN-ALTERED METAPLASTIC BREAST CARCINOMA. THE PRIMARY OBJECTIVE FOR COHORT B IS TO ASSESS THE EFFICACY OF MEN1611 AS MONOTHERAPY AS DETERMINED BY THE OBJECTIVE RESPONSE RATE AT 6 WEEKS.

SABINA AT CLINICALTRIALS.GOV

COUNTRY

STATUS

TUMOR TYPE

PHASE

N

SITES

PIK3CA/PTEN altered metaplastic breast cancer

8

28

II

Spain

Recruitment

TRIAL OVERVIEW

home_fondo_you_barra.jpg

PRESS RELEASE

home_fondo_you_barra.jpg

-----

SCIENTIFIC IMPACT

home_fondo_you_barra.jpg

--------

BLOG ARTICLES RELATED

home_fondo_you_barra.jpg

-----

TRIAL SITES

home_fondo_you_barra.jpg
Instituto Valenciano de Oncología (Spain) Hospital Universitario Virgen del Rocío (Spain) Onkologikoa (Spain) Hospital Universitario de Torrejón (Spain) Hospital Universitario Clínico San Cecilio de Granada (Spain) Institut Català d’ Oncologia L’Hospitalet (Spain) Hospital Universitari Vall D'Hebron (Spain)
Dr. Cortes and Dr. Llombart PHERain interview
Beyond Chemotherapy
Dr. Vanes Quiroga
Dr. Sofia Braga
Dr. Silvi Antolín
Dr. Escrivá de Romaní
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley

TRIAL RESUME

home_fondo_you_barra.jpg
bottom of page